Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?
07:41am, Wednesday, 18'th Dec 2024
Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into fur
TEVA stock soars 26%: What's going on with Teva Pharmaceuticals?
04:32am, Wednesday, 18'th Dec 2024
Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn's disease
Overlooked Stock: TEVA
04:50pm, Tuesday, 17'th Dec 2024
Teva Pharmaceutical (TEVA) closed at its highest stock price of the year after it and Sanofi (SNY) say their IBD treatment had higher remission in trial. George Tsilis looks at how the development can
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
02:25pm, Tuesday, 17'th Dec 2024
U.S.-traded shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and C
TD says Spyre has 'superior TL1A program' after Teva data
02:18pm, Tuesday, 17'th Dec 2024
TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to i
Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG
02:03pm, Tuesday, 17'th Dec 2024
BTIG analyst Julian Harrison notes that Teva's (TEVA) enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A asset that "they only own 50% rights to" plus $1B in dev
Teva price target raised to $25 from $23 at BofA
01:23pm, Tuesday, 17'th Dec 2024
BofA raised the firm's price target on Teva to $25 from $23 and keeps a Buy rating on the shares. The price target increase reflects the strong Phase 2 update for duvakitug as a treatment for inflamma
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
11:51am, Tuesday, 17'th Dec 2024
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical
10:24am, Tuesday, 17'th Dec 2024
Pharma stocks Pfizer Inc (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are in the spotlight today.
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
09:16am, Tuesday, 17'th Dec 2024
On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
Teva, Sanofi say drug to treat IBD met primary targets
07:35am, Tuesday, 17'th Dec 2024
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the h
Can Teva Return To All-Time Highs?
08:00am, Friday, 06'th Dec 2024
Teva Pharmaceutical stock has rebounded from lows, driven by debt reduction, halted price deflation in generics, and new product launches, making it a strong buy. Teva's innovative branded drugs and b
Pharma firm Teva to divest its business venture in Japan
06:39pm, Thursday, 05'th Dec 2024
Teva Pharmaceutical Industries said on Thursday it will transfer ownership of its business venture that sold generics in Japan to JKI.
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
06:00pm, Thursday, 05'th Dec 2024
TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund m
